Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Upreti

Showing results (11-20 of 64) with videos related to

Pageof 7
Sort By:
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 28, 2005
Determination of endogenous glycosaminoglycans derived disaccharides in human plasma by HPLC: validation and application in a clinical studyVijay V Upreti, Manoj Khurana, Donna S Cox, et al.
Journal of Clinical Pharmacology|September 2, 2008
Characterization of total plasma glycosaminoglycan levels in healthy volunteers following oral administration of a novel antithrombotic odiparcil with aspirin or enoxaparinAlan L Myers, Vijay V Upreti, Manoj Khurana, et al.
The Journal of the Association of Physicians of India|September 17, 2009
Osteogenesis imperfectaS K Bhadada, R Santosh, A Bhansali, et al.
Medical Journal, Armed Forces India|October 1, 2016
Malaria - the Master MasqueraderV Upreti, V Gera, L C Chamania, et al.
Clinical Pharmacology : Advances and Applications|August 18, 2020
Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or NotMichael Z Liao, Marloes Berkhout, Hans Prenen, et al.
Biomedical Chromatography : BMC|September 19, 2003
Quantitative determination of DRF-1042 in human plasma by HPLC: validation and application in clinical pharmacokineticsVijay V Upreti, Rao N V S Mamidi, Kasiram Katneni, et al.
Clinical Pharmacology and Therapeutics|September 25, 2023
A Mechanistic Physiologically-Based Pharmacokinetic Platform Model to Guide Adult and Pediatric Intravenous and Subcutaneous Dosing for Bispecific T Cell EngagersXinwen Zhang, Annie Lumen, Hansen Wong, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 24, 2022
Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanomaMalidi Ahamadi, Johannes Kast, Po-Wei Chen, et al.
Journal of Clinical Pharmacology|September 5, 2025
Clinical Pharmacology Characterization of the First-In-Class Oncolytic Viral Therapy T-VEC in Adults and Pediatric SubjectsXinwen Zhang, Bhavya Balu, Po-Wei Chen, et al.
Clinical Pharmacology : Advances and Applications|December 17, 2020
Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]Michael Z Liao, Johannes Kast, Marloes Berkhout, et al.
Pageof 7

Showing results (11-20 of 64) with videos related to

Sort By:
Pageof 7
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 28, 2005
Determination of endogenous glycosaminoglycans derived disaccharides in human plasma by HPLC: validation and application in a clinical studyVijay V Upreti, Manoj Khurana, Donna S Cox, et al.
Journal of Clinical Pharmacology|September 2, 2008
Characterization of total plasma glycosaminoglycan levels in healthy volunteers following oral administration of a novel antithrombotic odiparcil with aspirin or enoxaparinAlan L Myers, Vijay V Upreti, Manoj Khurana, et al.
The Journal of the Association of Physicians of India|September 17, 2009
Osteogenesis imperfectaS K Bhadada, R Santosh, A Bhansali, et al.
Medical Journal, Armed Forces India|October 1, 2016
Malaria - the Master MasqueraderV Upreti, V Gera, L C Chamania, et al.
Clinical Pharmacology : Advances and Applications|August 18, 2020
Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or NotMichael Z Liao, Marloes Berkhout, Hans Prenen, et al.
Biomedical Chromatography : BMC|September 19, 2003
Quantitative determination of DRF-1042 in human plasma by HPLC: validation and application in clinical pharmacokineticsVijay V Upreti, Rao N V S Mamidi, Kasiram Katneni, et al.
Clinical Pharmacology and Therapeutics|September 25, 2023
A Mechanistic Physiologically-Based Pharmacokinetic Platform Model to Guide Adult and Pediatric Intravenous and Subcutaneous Dosing for Bispecific T Cell EngagersXinwen Zhang, Annie Lumen, Hansen Wong, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 24, 2022
Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanomaMalidi Ahamadi, Johannes Kast, Po-Wei Chen, et al.
Journal of Clinical Pharmacology|September 5, 2025
Clinical Pharmacology Characterization of the First-In-Class Oncolytic Viral Therapy T-VEC in Adults and Pediatric SubjectsXinwen Zhang, Bhavya Balu, Po-Wei Chen, et al.
Clinical Pharmacology : Advances and Applications|December 17, 2020
Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]Michael Z Liao, Johannes Kast, Marloes Berkhout, et al.
Pageof 7